TRUMY
PINK Terumo Corp Unsponsored ADR$14.21 ↑ +0.00 (+0.00%) Trading Up from the previous close of $14.21, $0.08 below the day’s high of $14.29
- YTD change
- -2.00%
- vs 20-day SMA
- -2.53%
- vs 200-day SMA
- +1.67%
Price ranges
Price & Performance
+0.47 (+3.42%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 43.8% away from all-time highs of $25.27
- TRUMY is down 2% since the beginning of the year
- TRUMY is down 12% over the past 12 months
- TRUMY is down 9% over the past 1 month
TRUMY reads not so good: price sits above one of the two key moving averages, the 12-month move is -14.3%.
- Previous minute
- +$0.00
- Last hour
- -$0.03
- Last 5 days
- -0.35%
- vs 8-day SMA
- -1.33%
No alerts for TRUMY in the last day.
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
Terumo Corp. engages in the manufacture and sale of medical products and equipment. It operates through the following segments: Cardiac and Vascular Company, General Hospital Company, and Blood Management Company. The Cardiac and Vascular Company segment offers services and treatments including cardiac and vascular surgery and interventional therapies performed inside blood vessels. The General Hospital Company segment provides infusion and closed anticancer drug infusion systems, measuring devices system with communication functions, diabetes management, adhesion barrier, and peritoneal dialysis. The Blood Management Company segment offers a combination of apheresis collections, manual and automated whole blood processing, and pathogen reduction. The company was founded by Shibasaburo Kitasato on September 17, 1921 and is headquartered in Tokyo, Japan.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.
